Kforce Clinical Research Wins Operational Award from Merck
Kforce Clinical Research, a division of Kforce, Inc. (NASDAQ: KFRC), has won Merck & Co. Inc.'s "Outstanding Operational Award in Clinical Development" as part of Merck's 2007 Supplier Recognition Awards.
Kforce Clinical Research Wins Operational Award from Merck
TAMPA, Fla. – (Sept. 10, 2008) – Kforce Clinical Research, a division of Kforce, Inc. (NASDAQ: KFRC), has won Merck & Co. Inc.’s “Outstanding Operational Award in Clinical Development” as part of Merck's 2007 Supplier Recognition Awards. Kforce Clinical Research was one of 13 suppliers to be recognized at the pharmaceutical company’s Annual Supplier Recognition Forum at their headquarters in Whitehouse Station, N.J., on June 12.
Four years ago Merck established its “Plan to Win” program. In June of this year, Merck invited 75 suppliers to the Recognition Forum where key executives discussed Merck’s critical initiatives and these suppliers’ role in helping Merck achieve its Plan to Win. Ultimately, 13 suppliers were identified for their accomplishments in this initiative.
Kforce Clinical Research provides customized and flexible functional outsourcing solutions to the biopharmaceutical industry. It specializes in clinical monitoring, site and study management, drug safety, clinical data management, data entry, clinical programming and biostatistics. Where as other outsourcing providers either augment a company’s drug trial with people or handle all aspects of the trial, Kforce’s functional outsourcing model offers a flexible, tailored approach developed to mirror each company’s business model and address specific requirements of the drug trial itself.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
